Drug Interactions between deferiprone and exagamglogene autotemcel

ADJUST DOSING INTERVAL: Iron chelators may affect the efficacy of the autologous genome edited hematopoietic stem cell-based gene therapy, exagamglogene autotemcel. The exact mechanism is unknown; however, it may be related to the potential antiproliferative effects of iron chelators as well as interactions with the myeloablative conditioning regimen used prior to the infusion of exagamglogene autotemcel. Additionally, myelosuppressive iron chelators such as deferiprone, may increase the risk and/or severity of bone marrow suppression if given too soon after treatment with exagamglogene autotemcel.

MANAGEMENT: The manufacturer recommends discontinuing the use of iron chelators at least 7 days prior to the initiation of myeloablative conditioning, due to a potential interaction with the conditioning agent. After exagamglogene autotemcel administration, use of myelosuppressive and non-myelosuppressive iron chelators should be avoided for at least 6 months and 3 months, respectively. Phlebotomy can be used in lieu of iron chelation, when appropriate. Consultation with product labeling and local or institutional guidelines may be appropriate for further recommendations.